使用该小说的许可协议‘payload’ (drug-linker) technology developed by Nerviano Medical Sciences has been signed with Oxford BioTherapeutics: the company will use the platform developed in Italy to expand the of development its Antibody Drug Conjugates (ADC) portfolio for the treatment of cancer. The deal gives OBT access to a new 有效载荷 technology based on a next-generation duocarmycin analogue. Nerviano will receive undisclosed fees, development linked milestones and royalties for granting OBT access to its technology.

发表评论

请输入您的评论!
请在这里输入您的名字